December 2024 Gut Highlights
The BSG Gut Highlights from December 2024
Related Articles
Non–Anti-TNF Agents Safe as 1st-Line Rx Before Anti-TNFs
Treatment with vedolizumab or ustekinumab in CD, or vedolizumab in UC, followed by an anti–TNF was found to be safe.
Effects of glucagon-like peptide-1 receptor agonists on endoscopy outcomes: systematic review and meta-analysis
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to cause delayed gastric emptying; however, the effect on clinical outcomes during upper endoscopy and colonoscopy remains unclear.…
Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies
Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, carrying a greater risk of developing cirrhosis and its complications. For decades, pegylated…
Trends and cross-country inequality in the incidence of GI cancers among the working-age population from 1990 to 2021: a Global Burden of Disease 2021 analysis
Background GI cancers pose an increasing global health burden, with their impact on the working-age population (WAP) aged 15–64 years remaining largely unexplored despite the…
Welcome! You are invited to join a webinar: Gastro Bites: Navigating Pharmacological Treatment for Moderate-to-Severe Ulcerative Colitis. After registering, you will receive a confirmation email about joining the webinar.
Join us to hear directly from the experts! This Gastro Bites session provides the opportunity to gain valuable insights and ask questions directly to the…
Welcome! You are invited to join a webinar: Annual General Surgery Review Course – Part 2. After registering, you will receive a confirmation email about joining the webinar.
Welcome and Overview – Michael M. Awad, MD, PhD & Ivy Haskins, MD Surgical Critical Care/Trauma – Maggie Bosley, MD Breast/Endocrine – Amy Rosenbluth, MD…
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle…
Association of breast milk-derived arachidonic acid-induced infant gut dysbiosis with the onset of atopic dermatitis
Objective The specific breast milk-derived metabolites that mediate host–microbiota interactions and contribute to the onset of atopic dermatitis (AD) remain unknown and require further investigation.…
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
Background Cholangiocarcinoma (CCA) is a very difficult-to-treat cancer. Chemotherapies are little effective and response to immune checkpoint inhibitors is limited. Therefore, new therapeutic strategies need…
Cour Pharmaceuticals snags orphan drug designation for CNP-104 for the treatment of PBC
The FDA has granted Cour Pharmaceuticals orphan drug designation for CNP-104, a biodegradable nanoparticle in development for the treatment of primary biliary cholangitis, the company…
